1. The plasma adenosine 3':5'-cyclic monophosphate (cyclic AMP) response to intravenously administered glucagon has been studied in nine hyperthyroid, five hypothyroid and ten euthyroid patients.
Introduction
It has been suggested that some of the metabolic abnormalities in thyroid disease may be secondary to alterations in the metabolism of adenosine 3':5'-cyclic monophosphate (cyclic AMP) in tissues (Krishna, Hynie & Brodie, 1968; Levey, Skelton & Epstein, 1969a; Caldwell & Fain, 1971) . Investigations of this type have largely been concerned with heart and adipose tissue of experimental animals, although metabolic changes have also been studied in the liver in thyroid disease (Freedland, 1965; Dooner, Parada, Aliaga & Hoyl, 1967; Klion, Segal & Schaffner, 1971) . Cyclic AMP is widely accepted as the intracellular mediator of the hepatic effects of glucagon (Robison, Butcher & Sutherland, 1971) . Glucagon increases the content of cyclic AMP in liver in vivo (Pauk & Reddy, 1971) , in perfused liver in vitro (Exton, Robison, Sutherland & Park, 1971) , and in organ culture (Siddle, Kane-Maguire & Campbell, 1973) . It has also been shown that intravenous glucagon in man produces a large increase in plasma cyclic AMP concentration (Broadus, Kaminsky, Northcutt, Hardman, Sutherland & Liddle, 1970) and that the liver is the source of this cyclic AMP (Broadus et al., 1970; Liljenquist, Bomboy, Lewis, Sinclair-Smith, Felts, Lacy, Crofford & Liddle, 1974) . found that the rise in intracellular cyclic AMP produced by glucagon in rat liver in organ culture was increased by previous incubation with thyroid hormones. In order to ascertain whether thyroid status similarly affects hepatic production of cyclic AMP in man we have investigated plasma cyclic AMP concentration after administration of glucagon to patients with thyroid disease. Measurements have also been made of blood glucose, serum insulin and plasma non-esterified fatty acids (NEFA), both to aid in the interpretation of the cyclic AMP results and to compare with previous data (Levy, Adesman & Spergel, 1970) .
Patients and methods
Nine hyperthyroid patients, six female and three 27 o male (mean age 54·5 years; range 31-79), and five hypothyroid patients, four female and one male (mean age 53·8 years; range 34-65), were studied. The control group comprised ten euthyroid convalescent patients, seven female and three male (mean age 42·2 years; range 23-57). None of the patients had diabetes and all were within 10% of their ideal body weight. Informed consent for the study was obtained from all patients. The thyroid status of the patients was assessed clinically, by measurement of serum thyroxine iodine (Technicon), serum tri-iodothyronine (T3) (Hufner & Hesch, 1973) , thyopac-3 (Abbott), free thyroxine index (FTI) and by standard radioiodine uptake tests where appropriate. The values for all indices measured fell within the range appropriate to the assigned thyroid status for the individual patient. Full detailsof these measurements have been deposited as Clinical Science and Molecular Medicine Table 74 /11 with the Librarian, the Royal Society of Medicine, 1 Wimpole Street, London W17 8AE, from whom copies may be obtained on request.
After the patient had fasted overnight, a cannula was inserted into an antecubital vein, which was kept patent by a slow infusion of 154 mmol/l sodium chloride. Patients were then rested for 20 min before the base-line blood sample was drawn. After the intravenous injection of 1 mg of glucagon (Lilly) further blood samples were taken at 5, 15, 30, 60, 90 and 120 min. Blood for cyclic AMP measurement was taken into lithium sequestrene tubes, which were immediately placed on ice. A portion (2 ml) of 0·61 mol/l trichloroacetic acid was added to 2 ml of the separated plasma and the precipitated protein was removed by centrifugation. Trichloroacetic acid was removed from the deproteinized plasma with 4 x 10 ml of ether, and samples were stored at -20°C before assay. Standards were prepared in cyclic AMPfree plasma and treated in the same way as the samples. Cyclic AMP was measured by radioimmunoassay (Siddle et aI., 1973) . Blood glucose was measured by a glucose oxidase method using an Autoanalyser, serum insulin by the double antibody method of Hales & Randle (1963) and plasma NEFA by the method of Dole & Meinertz (1960) .
Results

Plasma cyclic AMP
There were no significant differences in the fasting plasma cyclic AMP concentrations between any of the groups studied. After intravenous injection of glucagon, plasma cyclic AMP rose to a peak at 15 min in all euthyroid and hyperthyroid subjects and then declined (Fig. 1) . The mean cyclic AMP concentration in hyperthyroid subjects was greater than in the euthyroid control subjects at all times after glucagon, and the peak concentration in the hyperthyroid group (1028 ±85 nmol/I, mean Essa) was significantly higher than in the euthyroid group (534 ± 73 nmol/l: P <0'001). There was no indication within either group that males and females responded differently. In neither group was there any significant correlation between peak cyclic AMP response and serum T3 concentration. The cyclic AMP response to glucagon in the hypothyroid group was significantly less than in the euthyroid group (Fig. 1) , with a mean concentration of252 ±62 nmol/I at 15 min (P<0·05). However, the response in hypothyroid subjects was consistently prolonged.
Blood glucose and serum insulin
The mean fasting blood glucose concentration was increased in the hyperthyroid group (4'59 ±0·22 mrnol/l, mean j ssx: P<0'02) and decreased in the hypothyroid group (3'28 ±0·29 mmolrl; P<O'I) compared with the euthyroid controls (3,91 ±0·15 mmolrl). The mean maximum glucose concentration after glucagon injection was similar in all three groups (Fig. 2) . The mean percentage increase in glucose concentration at 30 min relative to the fasting value The mean fasting NEFA concentration (Fig. 4 ) was higher in the hyperthyroid group (702±81 ,umol/l, mean j ssn: P<0'002) than in the euthyroid group (362 ± 33 ,umol/I),and the concentration in the hypothyroid group was intermediate (512 ± 64,umol!l; P<0·05 relative to the euthyroid group). After glucagon injection plasma NEFA concentration fell to a minimum at 30-60 min in the euthyroid and hyperthyroid groups, and then rose above the initial values by 120 min. In the hypothyroid group the fall in NEFA concentration was smaller and delayed, and there was no secondary rise by 120 min.
were 18·4±2·3 ,uunits/ml (mean j ssa) in the hyperthyroid group and 15·0±4·0 ,uunits/ml in the hypothyroid group, values which were not significantly different from that of the euthyroid group (12'6 ±2·0 ,uunits/ml) (P>0'05 for both).
The mean concentration measured after glucagon at 5 min in the hyperthyroid group (74'3 ± 16·6 ,uunits/ml, mean ±SEM) was not significantly different (P >0'5) from the euthyroid group (61'2 ± 6'2 ,uunits/ ml), but was reduced in the hypothyroid group (31'6 ±4·8 ,uunits/ml) (P<0'02) (Fig. 3) . This study has shown that the rise in plasma cyclic AMP concentration in response to intravenous glucagon is increased in hyperthyroid and decreased in D hypothyroid subjects compared with euthyroid controls (Fig. 1) .The increase in plasma cyclicAMP after glucagon is almost certainly due to hepatic production of the nucleotide (Broadus et al., 1970; Liljenquist et aI., 1974) . Insulin antagonizes the effect of glucagon on hepatic formation and release of cyclic AMP in animals (Park, Lewis & Exton, 1972; Kuster, Zapf & Jakob, 1973) .However, serum insulin concentrations (Fig. 3) would not in this way account for the differences in cyclicAMP concentration in the groups studied. The plasma cyclic AMP responses therefore suggest that hepatic cyclic AMP formation stimulated by glucagon is increased in hyperthyroidism and decreased in hypothyroidism although differences in release of hepatic cyclic AMP into the blood or in removal of cyclic AMP from the blood in the different thyroid states have not been excluded. These results are therefore compatible with the studies of on rat liver in vitro. There was no significant difference in basal cyclic AMP concentration, which may be derived from many tissues (Wehman, Blonde & Steiner, 1974) , between any of the three groups studied. Lin, Kopp & Tucci (1973) failed to find definite evidence ofan increase in total urinary excretion of cyclicAMP in hyperthyroidism. Jones, Ismail-Beigi & Edelman (1972) found that basal and adrenaline-stimulated adenylate cyclase activities ofliver homogenates were similar in hyper-, hypo-and euthyroid rats, but neither tissue cyclic AMP concentrations nor the effects of glucagon were studied. In rat adipose tissue, effects of thyroid hormones in increasing cyclic AMP formation with adrenaline have been demonstrated (Challoner & Allen, 1970; Caldwell & Fain, 1971 ) and may explain the increased lipolysis associated with hyperthyroidism. Studies of effects of thyroid hormones on adenylate cyclase and cyclicAMP phosphodiesterase of adipose tissue and heart in animals have produced conflicting and inconclusive results (Krishna et al., 1968; Mandel & Kuehl, 1967; Levey & Epstein, 1969; Frazer, Hess & Shanfield, 1969; Sobel, Dempsey & Cooper, 1969; Levey et al., 1969a, b; Broekhuysen & Ghislain, 1972 ).However, it appears possible from the present results and those of some previous authors that thyroid hormones modulate responsiveness of tissues to acutely acting hormones, as measured by cyclic AMP production.
The increased fasting blood glucose and NEFA concentrations in hyperthyroid subjects (Fig. 2 and Fig. 4 ) confirm previous results (Levy et aI., 1970; Marks, Kiem & Hills, 1960; Hales & Hyams, 1964; Doar, Stamp, Wynn & Audhya, 1969) . Stimulation of hepatic glucose production by glucagon is thought to be mediated by cyclic AMP . However, the increase in blood glucose after glucagon was least in hyperthyroid subjects, as previously reported (Levy et al., 1970) , although this group showed the greatest cyclic AMP response (Fig. 1) .
There has been controversy concerning serum insulin concentrations and response to glucose in thyroid disease (Hales & Hyams, 1964; Doar et al., 1969; Malaisse, Malaisse-Lagae & McCraw, 1967; Andreani, Menzinger, Fallucca, Aliberti, Tamburrano & Cassano, 1970; Cavagnini, Peracchi, Raggi, Bana, PontirolIi, Malinverni & Pinto, 1974) . The insulin responses to glucagon in the present study (Fig. 3 ) appear to differ from those reported by Levy et al. (1970) , who found that after treatment to render patients euthyroid the insulin response was increased in previously hyperthyroid subjects and decreased in previously hypothyroid subjects.
It seems likely that plasma cyclic AMP response to glucagon reflects an hepatic effect of thyroid hormone. Cyclic AMP measurement after intravenous glucagon could provide a tissue index of thyroid status more sensitive than those in current use.
